Belinostat – Uses, Dosage, Side Effects, Interactions

Beleodaq is a histone deacetylase (HDAC) inhibitor that exhibits pan-HDAC inhibition and potent growth inhibitory and pro-apoptotic activities in a variety of tumor cells, including PTCL cells, at nanomolar concentrations. None of the trials show any clinically relevant changes caused by Beleodaq on heart rate, PR duration, or QRS duration as measures of autonomic state, atrioventricular conduction or depolarization; there were no cases of Torsades de Pointes.

Use in Cancer

Belinostat is approved to treat:

• Peripheral T-cell lymphoma in patients whose disease has recurred (come back) or is refractory (does not respond to treatment).

This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that belinostat provides a clinical benefit in these patients.

Belinostat is also being studied in the treatment of other types of cancer.

Contraindications

• Anemia, bone marrow suppression, leukopenia, neutropenia, thrombocytopenia – Hematologic toxicity, including thrombocytopenia, leukopenia (neutropenia and lymphopenia), and anemia have been reported with belinostat therapy. Monitor complete blood cell counts prior to starting therapy and then weekly. Dose modifications may be necessary in patients with bone marrow suppression and should be determined by the absolute neutrophil count (ANC) and platelet count nadirs of the previous cycle of therapy. Platelet counts should be >= 50,000/mm3 and ANC > 1000/mm3 before starting each cycle.
• Chemotherapy, infection, sepsis – Serious infections, including pneumonia and sepsis, have occurred during treatment with belinostat; some occurrences have been fatal. Do not administer belinostat to patients with an active infection. Use caution in patients with a history of extensive or intensive chemotherapy, as they may be at higher risk of life-threatening infections.
• Hepatic disease – Abnormal liver function tests and fatal hepatic toxicity have been observed in patients receiving belinostat. Monitor liver function tests prior to the start of each cycle of therapy. Patients with signs of hepatic impairment or hepatic disease may require dose modification or discontinuation.
  Tumor lysis syndrome (TLS) – Tumor lysis syndrome (TLS) has occurred in patients treated with belinostat. Patients with high tumor burden or advanced-stage disease are at greater risk for developing TLS; consider tumor lysis prophylaxis with anti-hyperuricemic agents and hydration beginning 12—24 hours prior to treatment with belinostat in these patients. For TLS treatment, administer aggressive intravenous hydration and antihyperuricemic agents, correct electrolyte abnormalities, and monitor renal function.

Dosage

Strengths: 500 mg

Lymphoma

• 1,000 mg/m2 IV over 30 minutes once daily on days 1 to 5 of a 21-day cycle
• Duration of therapy: Repeat the cycle every 21 days until disease progression or unacceptable toxicity.
• Dose reduction, discontinuation, or interruption of therapy may be needed to manage adverse reactions.

Dose Adjustments

Hematologic toxicities:

• Nadir absolute neutrophil count less than 0.5 x 10(9)/L or platelet count less than 25 x 10(9)/L: Decrease dose by 25% (750 mg/m2)

Non-hematologic toxicities:

• Any Grade 3 or 4 adverse reaction: Decrease dose by 25% (750 mg/m2)
• Recurrence of Grade 3 or 4 adverse reaction after 2 dose reductions: Discontinue treatment

Patients with Reduced UGT1A1 Activity:

• Reduce the starting dose to 750 mg/m2 in patients known to be homozygous for the UGT1A1*28 allele.

Side Effects

The Most Common

• nausea
• diarrhea
• vomiting
• constipation
• headache
• tiredness
• decreased appetite
• pain at the injection site
• swelling of the hands, feet, or ankles
• rash
• fever, cough, chills, muscle aches, worsening skin problems, flu-like symptoms, or other signs of infection
• painful, frequent, burning or difficult urination
• unusual bleeding or bruising
• dizziness, weakness, excessive tiredness, pale skin, or shortness of breath
• yellowing of the skin or eyes, pain in the right upper stomach area, dark urine, or itching

More Common

• severe ongoing nausea, vomiting, or diarrhea;
• a fever, chills, muscle aches, flu-like symptoms,
• cough with mucus, chest pain, fast heartbeats, rapid breathing or shortness of breath;
• easy bruising, unusual bleeding, purple or red spots under your skin;
• pain or burning when you urinate;
• confusion, severe drowsiness, feeling very ill;
• liver problems–loss of appetite, stomach pain (upper right side), tiredness, itching, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes);
• low red blood cells (anemia)–pale skin, unusual tiredness, feeling light-headed or short of breath, cold hands and feet; or
• signs of tumor cell breakdown–tiredness, weakness, muscle cramps, nausea, vomiting, diarrhea, fast or slow heart rate, tingling in your hands and feet or around your mouth.

Rare

• chest pain
• confusion
• cough
• decreased urine
• dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
• dry mouth
• fainting
• fast heartbeat
• fever or chills
• increased thirst
• irregular heartbeat
• loss of appetite
• mood changes
• muscle pain or cramps
• nausea or vomiting
• numbness or tingling in the hands, feet, or lips
• pale skin
• pinpoint red spots on the skin
• rapid, shallow breathing
• sore throat
• sweating
• tenderness
• tightness in the chest
• troubled breathing with exertion
• unusual bleeding or bruising
• unusual tiredness or weakness
• unusual weight gain or loss

Drug Interaction

DRUG	INTERACTION
Abatacept	The risk or severity of adverse effects can be increased when Abatacept is combined with Belinostat.
Abciximab	The risk or severity of bleeding can be increased when Abciximab is combined with Belinostat.
Abemaciclib	The serum concentration of Abemaciclib can be increased when it is combined with Belinostat.
Abrocitinib	The serum concentration of Belinostat can be increased when it is combined with Abrocitinib.
Acenocoumarol	The metabolism of Acenocoumarol can be increased when combined with Belinostat.
Acetaminophen	The metabolism of Acetaminophen can be increased when combined with Belinostat.
Acetylsalicylic acid	The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Belinostat.
Acyclovir	The metabolism of Acyclovir can be increased when combined with Belinostat.
Adalimumab	The risk or severity of adverse effects can be increased when Adalimumab is combined with Belinostat.
Adenine	The metabolism of Belinostat can be decreased when combined with Adenine.
Adenovirus type 7 vaccine live	The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Belinostat.
Afatinib	The serum concentration of Belinostat can be increased when it is combined with Afatinib.
Agomelatine	The metabolism of Agomelatine can be increased when combined with Belinostat.
Albendazole	The metabolism of Albendazole can be increased when combined with Belinostat.
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Belinostat.
Alefacept	The risk or severity of adverse effects can be increased when Alefacept is combined with Belinostat.
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Belinostat.
Allogeneic thymus tissue	The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Belinostat.
Allopurinol	The risk or severity of adverse effects can be increased when Allopurinol is combined with Belinostat.
Alosetron	The metabolism of Alosetron can be increased when combined with Belinostat.
Alteplase	The risk or severity of bleeding can be increased when Alteplase is combined with Belinostat.
Altretamine	The risk or severity of adverse effects can be increased when Altretamine is combined with Belinostat.
Ambrisentan	The serum concentration of Ambrisentan can be increased when it is combined with Belinostat.
Aminophenazone	The metabolism of Aminophenazone can be increased when combined with Belinostat.
Aminophylline	The metabolism of Aminophylline can be increased when combined with Belinostat.
Amiodarone	The serum concentration of Belinostat can be increased when it is combined with Amiodarone.
Amitriptyline	The metabolism of Belinostat can be decreased when combined with Amitriptyline.
Amsacrine	The risk or severity of adverse effects can be increased when Amsacrine is combined with Belinostat.
Anagrelide	The metabolism of Anagrelide can be increased when combined with Belinostat.
Anakinra	The risk or severity of adverse effects can be increased when Anakinra is combined with Belinostat.
Ancrod	The risk or severity of bleeding can be increased when Ancrod is combined with Belinostat.
Anifrolumab	The risk or severity of adverse effects can be increased when Belinostat is combined with Anifrolumab.
Anistreplase	The risk or severity of bleeding can be increased when Anistreplase is combined with Belinostat.
Anthrax immune globulin	The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Belinostat.
Anthrax vaccine	The risk or severity of infection can be increased when Anthrax vaccine is combined with Belinostat.
antilymphocyte immunoglobulin	The risk or severity of adverse effects can be increased when Belinostat is combined with Antilymphocyte immunoglobulin (horse).
Antipyrine	The metabolism of Antipyrine can be increased when combined with Belinostat.
Antithrombin Alfa	The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Belinostat.
Antithrombin III human	The risk or severity of bleeding can be increased when Antithrombin III human is combined with Belinostat.
Antithymocyte immunoglobulin	The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Belinostat.
Apalutamide	The serum concentration of Belinostat can be decreased when it is combined with Apalutamide.
Apixaban	The serum concentration of Apixaban can be increased when it is combined with Belinostat.
Apremilast	The risk or severity of adverse effects can be increased when Belinostat is combined with Apremilast.
Ardeparin	The risk or severity of bleeding can be increased when Ardeparin is combined with Belinostat.
Argatroban	The risk or severity of bleeding can be increased when Argatroban is combined with Belinostat.
Arsenic trioxide	The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Belinostat.
Articaine	The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Articaine.
Asciminib	The serum concentration of Belinostat can be increased when it is combined with Asciminib.
Asenapine	The metabolism of Asenapine can be increased when combined with Belinostat.
COVID-19 Vaccine	The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Belinostat.
Asunaprevir	The serum concentration of Belinostat can be increased when it is combined with Asunaprevir.
Atazanavir	The metabolism of Belinostat can be decreased when combined with Atazanavir.
Avanafil	The serum concentration of Avanafil can be increased when it is combined with Belinostat.
Avatrombopag	The serum concentration of Avatrombopag can be increased when it is combined with Belinostat.
Axitinib	The metabolism of Axitinib can be increased when combined with Belinostat.
Azacitidine	The risk or severity of adverse effects can be increased when Azacitidine is combined with Belinostat.
Azathioprine	The risk or severity of adverse effects can be increased when Azathioprine is combined with Belinostat.
Azelastine	The metabolism of Azelastine can be increased when combined with Belinostat.
Bacillusantigen	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Belinostat.
BCG-I live antigen	The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Belinostat.
Bacillus	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Belinostat.
Baricitinib	The risk or severity of adverse effects can be increased when Belinostat is combined with Baricitinib.
Basiliximab	The risk or severity of adverse effects can be increased when Basiliximab is combined with Belinostat.
BCG vaccine	The risk or severity of infection can be increased when BCG vaccine is combined with Belinostat.
Beclomethasone dipropionate	The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Belinostat.
Belantamab mafodotin	The serum concentration of Belantamab mafodotin can be increased when it is combined with Belinostat.
Belatacept	The risk or severity of adverse effects can be increased when Belinostat is combined with Belatacept.
Belimumab	The risk or severity of adverse effects can be increased when Belinostat is combined with Belimumab.
Belumosudil	The risk or severity of adverse effects can be increased when Belinostat is combined with Belumosudil.
Bemiparin	The risk or severity of bleeding can be increased when Bemiparin is combined with Belinostat.
Bendamustine	The risk or severity of adverse effects can be increased when Belinostat is combined with Bendamustine.
Bendroflumethiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Belinostat.
Benzocaine	The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Benzocaine.
Benzthiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Belinostat.
Benzyl alcohol	The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Benzyl alcohol.
Berotralstat	The serum concentration of Berotralstat can be increased when it is combined with Belinostat.
Betamethasone	The risk or severity of adverse effects can be increased when Betamethasone is combined with Belinostat.
Betaxolol	The metabolism of Betaxolol can be increased when combined with Belinostat.
Betrixaban	The serum concentration of Betrixaban can be increased when it is combined with Belinostat.
Bexarotene	The risk or severity of adverse effects can be increased when Bexarotene is combined with Belinostat.
Bimekizumab	The risk or severity of adverse effects can be increased when Belinostat is combined with Bimekizumab.
Binimetinib	The serum concentration of Binimetinib can be increased when it is combined with Belinostat.
Bisoprolol	The serum concentration of Belinostat can be increased when it is combined with Bisoprolol.
Bivalirudin	The risk or severity of bleeding can be increased when Bivalirudin is combined with Belinostat.
Bleomycin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Belinostat.
Blinatumomab	The risk or severity of adverse effects can be increased when Belinostat is combined with Blinatumomab.
Bordetella pertussis	The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Belinostat.
Bortezomib	The risk or severity of adverse effects can be increased when Bortezomib is combined with Belinostat.
Bosutinib	The risk or severity of adverse effects can be increased when Belinostat is combined with Bosutinib.
Brentuximab vedotin	The risk or severity of adverse effects can be increased when Belinostat is combined with Brentuximab vedotin.
Brodalumab	The risk or severity of adverse effects can be increased when Belinostat is combined with Brodalumab.
Bromazepam	The metabolism of Bromazepam can be increased when combined with Belinostat.
Bromotheophylline	The metabolism of Bromotheophylline can be increased when combined with Belinostat.
Budesonide	The risk or severity of adverse effects can be increased when Budesonide is combined with Belinostat.
Bupivacaine	The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Bupivacaine.
Busulfan	The risk or severity of adverse effects can be increased when Busulfan is combined with Belinostat.
Butacaine	The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Butacaine.
Butamben	The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Butamben.
Cabazitaxel	The risk or severity of adverse effects can be increased when Belinostat is combined with Cabazitaxel.
Cabergoline	The serum concentration of Cabergoline can be increased when it is combined with Belinostat.

Canagliflozin	The serum concentration of Belinostat can be increased when it is combined with Canagliflozin.
Canakinumab	The risk or severity of adverse effects can be increased when Belinostat is combined with Canakinumab.
Cangrelor	The risk or severity of bleeding can be increased when Cangrelor is combined with Belinostat.
Capecitabine	The risk or severity of adverse effects can be increased when Capecitabine is combined with Belinostat.
Caplacizumab	The risk or severity of bleeding can be increased when Caplacizumab is combined with Belinostat.
Capmatinib	The serum concentration of Belinostat can be increased when it is combined with Capmatinib.
Capsaicin	The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Capsaicin.
Carbamazepine	The metabolism of Belinostat can be increased when combined with Carbamazepine.
Carboplatin	The risk or severity of adverse effects can be increased when Carboplatin is combined with Belinostat.
Carfilzomib	The risk or severity of adverse effects can be increased when Belinostat is combined with Carfilzomib.
Carmustine	The risk or severity of adverse effects can be increased when Carmustine is combined with Belinostat.
Carvedilol	The serum concentration of Belinostat can be increased when it is combined with Carvedilol.
Ceritinib	The serum concentration of Ceritinib can be increased when it is combined with Belinostat.
Certolizumab pegol	The risk or severity of adverse effects can be increased when Belinostat is combined with Certolizumab pegol.
Chlorambucil	The risk or severity of adverse effects can be increased when Chlorambucil is combined with Belinostat.
Chloramphenicol	The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Belinostat.
Chloroprocaine	The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Chloroprocaine.
Chlorothiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Belinostat.
Chlorpromazine	The metabolism of Chlorpromazine can be increased when combined with Belinostat.
Chlorzoxazone	The metabolism of Chlorzoxazone can be increased when combined with Belinostat.
Ciclesonide	The risk or severity of adverse effects can be increased when Ciclesonide is combined with Belinostat.
Cilostazol	The risk or severity of bleeding can be increased when Cilostazol is combined with Belinostat.
Cinacalcet	The metabolism of Cinacalcet can be increased when combined with Belinostat.
Cinchocaine	The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Cinchocaine.
Cinnarizine	The metabolism of Cinnarizine can be increased when combined with Belinostat.
Cisplatin	The risk or severity of adverse effects can be increased when Cisplatin is combined with Belinostat.
Cladribine	The risk or severity of adverse effects can be increased when Cladribine is combined with Belinostat.
Clarithromycin	The serum concentration of Belinostat can be increased when it is combined with Clarithromycin.
Clobazam	The serum concentration of Belinostat can be increased when it is combined with Clobazam.
Clobetasol propionate	The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Belinostat.
Clofarabine	The risk or severity of adverse effects can be increased when Clofarabine is combined with Belinostat.
Clofazimine	The serum concentration of Belinostat can be increased when it is combined with Clofazimine.
Clomifene	The serum concentration of Belinostat can be increased when it is combined with Clomifene.
Clomipramine	The metabolism of Clomipramine can be increased when combined with Belinostat.
Clonidine	The metabolism of Clonidine can be increased when combined with Belinostat.
Clopidogrel	The risk or severity of bleeding can be increased when Clopidogrel is combined with Belinostat.
Clostridium	The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Belinostat.
Clozapine	The risk or severity of neutropenia can be increased when Belinostat is combined with Clozapine.
Cobicistat	The serum concentration of Belinostat can be increased when it is combined with Cobicistat.
Cobimetinib	The serum concentration of Cobimetinib can be increased when it is combined with Belinostat.
Cocaine	The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Cocaine.
Colchicine	The serum concentration of Belinostat can be increased when it is combined with Colchicine.
Conivaptan	The serum concentration of Belinostat can be increased when it is combined with Conivaptan.
Conjugated estrogens	The metabolism of Conjugated estrogens can be increased when combined with Belinostat.
Copanlisib	The serum concentration of Copanlisib can be increased when it is combined with Belinostat.
Corticotropin	The risk or severity of adverse effects can be increased when Corticotropin is combined with Belinostat.
Cortisone acetate	The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Belinostat.
Corynebacterium	The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Belinostat.
Crizotinib	The serum concentration of Belinostat can be increased when it is combined with Crizotinib.
Curcumin	The serum concentration of Belinostat can be increased when it is combined with Curcumin.
Cyanocobalamin	The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Belinostat.
Cyclobenzaprine	The metabolism of Cyclobenzaprine can be increased when combined with Belinostat.
Cyclopenthiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Belinostat.
Cyclophosphamide	The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Belinostat.
Cyclosporine	Belinostat may increase the immunosuppressive activities of Cyclosporine.
Cyclothiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Belinostat.
Cytarabine	The risk or severity of adverse effects can be increased when Cytarabine is combined with Belinostat.
Dabigatran	The risk or severity of bleeding can be increased when Dabigatran is combined with Belinostat.
Dabigatran etexilate	The serum concentration of Dabigatran etexilate can be increased when it is combined with Belinostat.
Dabrafenib	The metabolism of Belinostat can be decreased when combined with Dabrafenib.
Dacarbazine	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Belinostat.
Daclatasvir	The serum concentration of Belinostat can be increased when it is combined with Daclatasvir.
Dacomitinib	The metabolism of Belinostat can be decreased when combined with Dacomitinib.
Dactinomycin	The risk or severity of adverse effects can be increased when Dactinomycin is combined with Belinostat.
Dalteparin	The risk or severity of bleeding can be increased when Dalteparin is combined with Belinostat.
Danaparoid	The risk or severity of bleeding can be increased when Danaparoid is combined with Belinostat.
Dapagliflozin	The metabolism of Dapagliflozin can be increased when combined with Belinostat.
Daptomycin	The serum concentration of Belinostat can be increased when it is combined with Daptomycin.
Darbepoetin alfa	The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Belinostat.
Darolutamide	The serum concentration of Darolutamide can be increased when it is combined with Belinostat.
Darunavir	The serum concentration of Belinostat can be increased when it is combined with Darunavir.
Dasabuvir	The metabolism of Belinostat can be decreased when combined with Dasabuvir.
Dasatinib	The risk or severity of adverse effects can be increased when Dasatinib is combined with Belinostat.
Daunorubicin	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Belinostat.
Decitabine	The risk or severity of adverse effects can be increased when Decitabine is combined with Belinostat.
Deferasirox	The metabolism of Belinostat can be decreased when combined with Deferasirox.
Defibrotide	The risk or severity of bleeding can be increased when Defibrotide is combined with Belinostat.
Deflazacort	The risk or severity of adverse effects can be increased when Belinostat is combined with Deflazacort.
Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Belinostat.
Desirudin	The risk or severity of bleeding can be increased when Desirudin is combined with Belinostat.
Desogestrel	The metabolism of Belinostat can be increased when combined with Desogestrel.
Desoximetasone	The risk or severity of adverse effects can be increased when Desoximetasone is combined with Belinostat.
Deucravacitinib	The risk or severity of adverse effects can be increased when Belinostat is combined with Deucravacitinib.
Dexamethasone	The risk or severity of adverse effects can be increased when Dexamethasone is combined with Belinostat.
Dexfenfluramine	The metabolism of Dexfenfluramine can be increased when combined with Belinostat.
Dexrazoxane	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Belinostat.
Dextran	The risk or severity of bleeding can be increased when Dextran is combined with Belinostat.
Diclofenac	The metabolism of Diclofenac can be increased when combined with Belinostat.
Dicoumarol	The risk or severity of bleeding can be increased when Dicoumarol is combined with Belinostat.
Difluocortolone	The risk or severity of adverse effects can be increased when Belinostat is combined with Difluocortolone.
Digitoxin	The serum concentration of Digitoxin can be increased when it is combined with Belinostat.
Digoxin	The serum concentration of Digoxin can be increased when it is combined with Belinostat.
Dihydralazine	The metabolism of Dihydralazine can be increased when combined with Belinostat.
Dimethyl fumarate	The risk or severity of adverse effects can be increased when Belinostat is combined with Dimethyl fumarate.
Dinutuximab	The risk or severity of adverse effects can be increased when Belinostat is combined with Dinutuximab.
Diosmin	The serum concentration of Belinostat can be increased when it is combined with Diosmin.
Diphenhydramine	The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Diphenhydramine.
Dipyridamole	The risk or severity of bleeding can be increased when Dipyridamole is combined with Belinostat.
Diroximel fumarate	The risk or severity of adverse effects can be increased when Belinostat is combined with Diroximel fumarate.

Domperidone	The metabolism of Domperidone can be increased when combined with Belinostat.
Doxepin	The metabolism of Doxepin can be increased when combined with Belinostat.
Doxorubicin	The risk or severity of adverse effects can be increased when Doxorubicin is combined with Belinostat.
Dronedarone	The serum concentration of Belinostat can be increased when it is combined with Dronedarone.
Drotrecogin alfa	The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Belinostat.
Duvelisib	The serum concentration of Duvelisib can be increased when it is combined with Belinostat.
Dyclonine	The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Dyclonine.
Ebola Zaire vaccine	The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Belinostat.
Eculizumab	The risk or severity of adverse effects can be increased when Eculizumab is combined with Belinostat.
Edetic acid	The risk or severity of bleeding can be increased when Edetic acid is combined with Belinostat.
Edoxaban	The serum concentration of Edoxaban can be increased when it is combined with Belinostat.
Efalizumab	The risk or severity of adverse effects can be increased when Efalizumab is combined with Belinostat.
Efavirenz	The metabolism of Belinostat can be increased when combined with Efavirenz.
Elagolix	The serum concentration of Belinostat can be increased when it is combined with Elagolix.
Elbasvir	The serum concentration of Elbasvir can be increased when it is combined with Belinostat.
Eliglustat	The serum concentration of Belinostat can be increased when it is combined with Eliglustat.
Eltrombopag	The metabolism of Belinostat can be decreased when combined with Eltrombopag.
Emapalumab	The risk or severity of adverse effects can be increased when Belinostat is combined with Emapalumab.
Enasidenib	The metabolism of Belinostat can be decreased when combined with Enasidenib.
Enfortumab vedotin	The serum concentration of Enfortumab vedotin can be increased when it is combined with Belinostat.
Enoxaparin	The risk or severity of bleeding can be increased when Enoxaparin is combined with Belinostat.
Entecavir	The metabolism of Entecavir can be increased when combined with Belinostat.
Entrectinib	The serum concentration of Belinostat can be increased when it is combined with Entrectinib.
Epirubicin	The risk or severity of adverse effects can be increased when Epirubicin is combined with Belinostat.
Epoprostenol	The risk or severity of bleeding can be increased when Epoprostenol is combined with Belinostat.
Eptifibatide	The risk or severity of bleeding can be increased when Eptifibatide is combined with Belinostat.
Erdafitinib	The serum concentration of Belinostat can be increased when it is combined with Erdafitinib.
Eribulin	The risk or severity of adverse effects can be increased when Belinostat is combined with Eribulin.
Erlotinib	The metabolism of Belinostat can be decreased when combined with Erlotinib.
Ertugliflozin	The metabolism of Belinostat can be decreased when combined with Ertugliflozin.
Erythromycin	The serum concentration of Belinostat can be increased when it is combined with Erythromycin.
Erythropoietin	The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Belinostat.
Estradiol	The metabolism of Estradiol can be increased when combined with Belinostat.
Estradiol acetate	The metabolism of Estradiol acetate can be increased when combined with Belinostat.
Estradiol benzoate	The metabolism of Estradiol benzoate can be increased when combined with Belinostat.
Estradiol cypionate	The metabolism of Estradiol cypionate can be increased when combined with Belinostat.
Estradiol dienanthate	The metabolism of Estradiol dienanthate can be increased when combined with Belinostat.
Estradiol valerate	The metabolism of Estradiol valerate can be increased when combined with Belinostat.
Estramustine	The risk or severity of adverse effects can be increased when Estramustine is combined with Belinostat.
Estrone sulfate	The metabolism of Estrone sulfate can be increased when combined with Belinostat.
Etanercept	The risk or severity of adverse effects can be increased when Etanercept is combined with Belinostat.
Ethanol	The metabolism of Ethanol can be increased when combined with Belinostat.
Ethinylestradiol	The metabolism of Belinostat can be increased when combined with Ethinylestradiol.
Ethyl chloride	The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Ethyl chloride.
Etidocaine	The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Etidocaine.
Etoposide	The risk or severity of adverse effects can be increased when Etoposide is combined with Belinostat.
Etoricoxib	The metabolism of Etoricoxib can be increased when combined with Belinostat.
Everolimus	The risk or severity of adverse effects can be increased when Everolimus is combined with Belinostat.
Favipiravir	The serum concentration of Belinostat can be increased when it is combined with Favipiravir.
Fedratinib	The serum concentration of Belinostat can be increased when it is combined with Fedratinib.
Fenfluramine	The metabolism of Fenfluramine can be increased when combined with Belinostat.
Fexinidazole	The metabolism of Fexinidazole can be increased when combined with Belinostat.
Fexofenadine	The serum concentration of Belinostat can be increased when it is combined with Fexofenadine.
Filgotinib	The risk or severity of adverse effects can be increased when Belinostat is combined with Filgotinib.
Fingolimod	Belinostat may increase the immunosuppressive activities of Fingolimod.
Flecainide	The metabolism of Flecainide can be increased when combined with Belinostat.
Flibanserin	The serum concentration of Belinostat can be increased when it is combined with Flibanserin.
Floxuridine	The risk or severity of adverse effects can be increased when Floxuridine is combined with Belinostat.
Fluconazole	The serum concentration of Belinostat can be increased when it is combined with Fluconazole.
Flucytosine	The risk or severity of adverse effects can be increased when Flucytosine is combined with Belinostat.
Fludarabine	The risk or severity of adverse effects can be increased when Fludarabine is combined with Belinostat.
Fludrocortisone	The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Belinostat.
Fluindione	The risk or severity of bleeding can be increased when Fluindione is combined with Belinostat.
Flunarizine	The metabolism of Flunarizine can be increased when combined with Belinostat.
Flunisolide	The risk or severity of adverse effects can be increased when Flunisolide is combined with Belinostat.
Flunitrazepam	The metabolism of Belinostat can be decreased when combined with Flunitrazepam.
Fluocinolone acetonide	The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Belinostat.
Fluocinonide	The risk or severity of adverse effects can be increased when Fluocinonide is combined with Belinostat.
Fluocortolone	The risk or severity of adverse effects can be increased when Belinostat is combined with Fluocortolone.
Fluorometholone	The risk or severity of adverse effects can be increased when Fluorometholone is combined with Belinostat.
Fluorouracil	The risk or severity of adverse effects can be increased when Fluorouracil is combined with Belinostat.
Fluoxetine	The metabolism of Fluoxetine can be increased when combined with Belinostat.
Flupentixol	The risk or severity of myelosuppression can be increased when Flupentixol is combined with Belinostat.
Fluprednisolone	The risk or severity of adverse effects can be increased when Belinostat is combined with Fluprednisolone.
Flurbiprofen	The metabolism of Belinostat can be decreased when combined with Flurbiprofen.
Flutamide	The metabolism of Flutamide can be increased when combined with Belinostat.
Fluticasone	The risk or severity of adverse effects can be increased when Belinostat is combined with Fluticasone.
Fluticasone furoate	The risk or severity of adverse effects can be increased when Belinostat is combined with Fluticasone furoate.
Fluticasone propionate	The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Belinostat.
Fluvoxamine	The metabolism of Fluvoxamine can be increased when combined with Belinostat.
Fondaparinux	The risk or severity of bleeding can be increased when Fondaparinux is combined with Belinostat.
Fostamatinib	The metabolism of Belinostat can be decreased when combined with Fostamatinib.
Fostemsavir	The serum concentration of Fostemsavir can be increased when it is combined with Belinostat.
Frovatriptan	The metabolism of Frovatriptan can be increased when combined with Belinostat.
Futibatinib	The serum concentration of Futibatinib can be increased when it is combined with Belinostat.
Gallium nitrate	The risk or severity of adverse effects can be increased when Belinostat is combined with Gallium nitrate.
Gemcitabine	The risk or severity of adverse effects can be increased when Gemcitabine is combined with Belinostat.
Gemfibrozil	The metabolism of Belinostat can be decreased when combined with Gemfibrozil.
Gemtuzumab ozogamicin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Belinostat.
Gilteritinib	The serum concentration of Gilteritinib can be increased when it is combined with Belinostat.
Glasdegib	The serum concentration of Belinostat can be increased when it is combined with Glasdegib.
Glatiramer	The risk or severity of adverse effects can be increased when Belinostat is combined with Glatiramer.
Glecaprevir	The metabolism of Belinostat can be decreased when combined with Glecaprevir.
Golimumab	The risk or severity of adverse effects can be increased when Belinostat is combined with Golimumab.
Grazoprevir	The serum concentration of Grazoprevir can be increased when it is combined with Belinostat.
Grepafloxacin	The metabolism of Grepafloxacin can be increased when combined with Belinostat.
Guanabenz	The metabolism of Guanabenz can be increased when combined with Belinostat.

Ketoconazole	The metabolism of Belinostat can be decreased when combined with Ketoconazole.
Lamotrigine	The metabolism of Belinostat can be increased when combined with Lamotrigine.
Lapatinib	The serum concentration of Belinostat can be increased when it is combined with Lapatinib.
Larotrectinib	The serum concentration of Larotrectinib can be increased when it is combined with Belinostat.
Lasmiditan	The serum concentration of Belinostat can be increased when it is combined with Lasmiditan.
Ledipasvir	The serum concentration of Belinostat can be increased when it is combined with Ledipasvir.
Lefamulin	The serum concentration of Lefamulin can be increased when it is combined with Belinostat.
Leflunomide	The risk or severity of adverse effects can be increased when Belinostat is combined with Leflunomide.
Lemborexant	The serum concentration of Lemborexant can be increased when it is combined with Belinostat.
Lenalidomide	The risk or severity of adverse effects can be increased when Lenalidomide is combined with Belinostat.
Lenvatinib	The serum concentration of Lenvatinib can be increased when it is combined with Belinostat.
Lepirudin	The risk or severity of bleeding can be increased when Lepirudin is combined with Belinostat.
Levobupivacaine	The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Levobupivacaine.
Levoketoconazole	The serum concentration of Belinostat can be increased when it is combined with Levoketoconazole.
Lidocaine	The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Lidocaine.
Linagliptin	The serum concentration of Belinostat can be increased when it is combined with Linagliptin.
Linezolid	The risk or severity of adverse effects can be increased when Linezolid is combined with Belinostat.
Lipegfilgrastim	Belinostat may increase the myelosuppressive activities of Lipegfilgrastim.
Lofexidine	The metabolism of Lofexidine can be increased when combined with Belinostat.
Lomefloxacin	The metabolism of Lomefloxacin can be increased when combined with Belinostat.
Lomitapide	The serum concentration of Belinostat can be increased when it is combined with Lomitapide.
Lomustine	The risk or severity of adverse effects can be increased when Lomustine is combined with Belinostat.
Lonafarnib	The serum concentration of Belinostat can be increased when it is combined with Lonafarnib.
Loncastuximab tesirine	The serum concentration of Loncastuximab tesirine can be increased when it is combined with Belinostat.
Loperamide	The serum concentration of Belinostat can be increased when it is combined with Loperamide.
Lopinavir	The serum concentration of Belinostat can be increased when it is combined with Lopinavir.
Lorcaserin	The metabolism of Lorcaserin can be increased when combined with Belinostat.
Loxapine	The serum concentration of Belinostat can be increased when it is combined with Loxapine.
Lumacaftor	The serum concentration of Belinostat can be decreased when it is combined with Lumacaftor.
Lusutrombopag	The serum concentration of Lusutrombopag can be increased when it is combined with Belinostat.
Magnesium	The serum concentration of Magnesium can be decreased when it is combined with Belinostat.
Mannitol	The serum concentration of Belinostat can be increased when it is combined with Mannitol.
Maprotiline	The metabolism of Maprotiline can be increased when combined with Belinostat.
Maribavir	The serum concentration of Belinostat can be increased when it is combined with Maribavir.
Measles virus vaccine	The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Belinostat.
Mechlorethamine	The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Belinostat.
Mefenamic acid	The metabolism of Mefenamic acid can be increased when combined with Belinostat.
Mefloquine	The serum concentration of Belinostat can be increased when it is combined with Mefloquine.
Melatonin	The metabolism of Melatonin can be increased when combined with Belinostat.
Meloxicam	The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Meloxicam.
Melphalan	The risk or severity of adverse effects can be increased when Melphalan is combined with Belinostat.

Methotrexate	The risk or severity of adverse effects can be increased when Methotrexate is combined with Belinostat.
Methoxy polyethylene	The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Belinostat.
Methylene blue	The serum concentration of Belinostat can be increased when it is combined with Methylene blue.
Methylprednisolone	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Belinostat.
Metoclopramide	The metabolism of Metoclopramide can be increased when combined with Belinostat.
Mexiletine	The metabolism of Mexiletine can be increased when combined with Belinostat.
Mianserin	The metabolism of Mianserin can be increased when combined with Belinostat.
Mifepristone	The serum concentration of Belinostat can be increased when it is combined with Mifepristone.
Mirabegron	The serum concentration of Belinostat can be increased when it is combined with Mirabegron.
Mirtazapine	The metabolism of Mirtazapine can be increased when combined with Belinostat.
Mitapivat	The metabolism of Belinostat can be increased when combined with Mitapivat.
Mitomycin	The risk or severity of adverse effects can be increased when Mitomycin is combined with Belinostat.
Mitoxantrone	The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Belinostat.
Moderna COVID	The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Belinostat.
Modified vaccinia ankara	The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Belinostat.
Mometasone furoate	The risk or severity of adverse effects can be increased when Belinostat is combined with Mometasone furoate.
Monomethyl fumarate	The risk or severity of adverse effects can be increased when Belinostat is combined with Monomethyl fumarate.
Morphine	The serum concentration of Belinostat can be increased when it is combined with Morphine.
Mosunetuzumab	The risk or severity of adverse effects can be increased when Belinostat is combined with Mosunetuzumab.
Mumps virus	The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Belinostat.
Muromonab	The risk or severity of adverse effects can be increased when Muromonab is combined with Belinostat.
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Belinostat.
Mycophenolic acid	The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Belinostat.
Nabumetone	The metabolism of Nabumetone can be increased when combined with Belinostat.
Nadroparin	The risk or severity of bleeding can be increased when Nadroparin is combined with Belinostat.
Naproxen	The metabolism of Naproxen can be increased when combined with Belinostat.
Natalizumab	The risk or severity of adverse effects can be increased when Belinostat is combined with Natalizumab.
Nelarabine	The risk or severity of adverse effects can be increased when Nelarabine is combined with Belinostat.
Nelfinavir	The metabolism of Belinostat can be increased when combined with Nelfinavir.
Neratinib	The serum concentration of Belinostat can be increased when it is combined with Neratinib.
Netupitant	The serum concentration of Belinostat can be increased when it is combined with Netupitant.
Nifedipine	The metabolism of Nifedipine can be increased when combined with Belinostat.
Nilotinib	The metabolism of Belinostat can be decreased when combined with Nilotinib.
Nimesulide	The risk or severity of bleeding can be increased when Nimesulide is combined with Belinostat.
Nintedanib	The serum concentration of Nintedanib can be increased when it is combined with Belinostat.
Norgestimate	The serum concentration of Belinostat can be increased when it is combined with Norgestimate.
Nortriptyline	The serum concentration of Nortriptyline can be increased when it is combined with Belinostat.
Nuvaxovid	The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Belinostat.
Obinutuzumab	The risk or severity of adverse effects can be increased when Belinostat is combined with Obinutuzumab.
Ocrelizumab	Ocrelizumab may increase the immunosuppressive activities of Belinostat.
Ofatumumab	The risk or severity of adverse effects can be increased when Belinostat is combined with Ofatumumab.
Olanzapine	The metabolism of Olanzapine can be increased when combined with Belinostat.
Olaparib	The risk or severity of adverse effects can be increased when Belinostat is combined with Olaparib.
Omadacycline	The serum concentration of Omadacycline can be increased when it is combined with Belinostat.
Ombitasvir	The metabolism of Belinostat can be decreased when combined with Ombitasvir.
Ondansetron	The metabolism of Ondansetron can be increased when combined with Belinostat.
Osimertinib	The serum concentration of Osimertinib can be increased when it is combined with Belinostat.
Oxaliplatin	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Belinostat.
Oxetacaine	The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Oxetacaine.
Oxtriphylline	The metabolism of Oxtriphylline can be increased when combined with Belinostat.
Oxybuprocaine	The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Oxybuprocaine.
Ozanimod	The risk or severity of adverse effects can be increased when Belinostat is combined with Ozanimod.
Paclitaxel	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Belinostat.
Pacritinib	The serum concentration of Belinostat can be increased when it is combined with Pacritinib.
Palbociclib	The risk or severity of adverse effects can be increased when Belinostat is combined with Palbociclib.
Palifermin	The therapeutic efficacy of Palifermin can be decreased when used in combination with Belinostat.
Paliperidone	The serum concentration of Belinostat can be increased when it is combined with Paliperidone.
Panobinostat	The risk or severity of adverse effects can be increased when Belinostat is combined with Panobinostat.
Paritaprevir	The metabolism of Belinostat can be decreased when combined with Paritaprevir.
Parnaparin	The risk or severity of bleeding can be increased when Parnaparin is combined with Belinostat.
Paroxetine	The metabolism of Paroxetine can be increased when combined with Belinostat.
Pazopanib	The metabolism of Belinostat can be decreased when combined with Pazopanib.
Pegaspargase	The risk or severity of adverse effects can be increased when Pegaspargase is combined with Belinostat.
Pegcetacoplan	The risk or severity of adverse effects can be increased when Belinostat is combined with Pegcetacoplan.
Peginesatide	The risk or severity of Thrombosis can be increased when Peginesatide is combined with Belinostat.
Peginterferon alfa-2a	The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Belinostat.
Peginterferon alfa-2b	The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Belinostat.
Peginterferon beta-1a	The risk or severity of adverse effects can be increased when Belinostat is combined with Peginterferon beta-1a.
Pemetrexed	The risk or severity of adverse effects can be increased when Pemetrexed is combined with Belinostat.
Penciclovir	The metabolism of Penciclovir can be increased when combined with Belinostat.
Penicillamine	The risk or severity of adverse effects can be increased when Penicillamine is combined with Belinostat.
Pentosan polysulfate	The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Belinostat.
Pentostatin	The risk or severity of adverse effects can be increased when Pentostatin is combined with Belinostat.
Pentoxifylline	The risk or severity of bleeding can be increased when Pentoxifylline is combined with Belinostat.
Perampanel	The metabolism of Perampanel can be increased when combined with Belinostat.
Perphenazine	The metabolism of Perphenazine can be increased when combined with Belinostat.
Pertussis vaccine	The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Belinostat.
Pexidartinib	The metabolism of Belinostat can be decreased when combined with Pexidartinib.
Phenindione	The risk or severity of bleeding can be increased when Phenindione is combined with Belinostat.
Phenobarbital	The metabolism of Belinostat can be increased when combined with Phenobarbital.
Phenol	The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Phenol.
Phenprocoumon	The risk or severity of bleeding can be increased when Phenprocoumon is combined with Belinostat.
Phenylalanine	The risk or severity of adverse effects can be increased when Phenylalanine is combined with Belinostat.
Phenytoin	The metabolism of Belinostat can be increased when combined with Phenytoin.
Pibrentasvir	The metabolism of Belinostat can be decreased when combined with Pibrentasvir.
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Belinostat.
Pimozide	The metabolism of Pimozide can be increased when combined with Belinostat.
Pirfenidone	The risk or severity of adverse effects can be increased when Pirfenidone is combined with Belinostat.
Pitolisant	The serum concentration of Belinostat can be increased when it is combined with Pitolisant.
Polythiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Belinostat.
Pomalidomide	The risk or severity of adverse effects can be increased when Belinostat is combined with Pomalidomide.
Ponatinib	The risk or severity of adverse effects can be increased when Belinostat is combined with Ponatinib.
Ponesimod	The risk or severity of adverse effects can be increased when Belinostat is combined with Ponesimod.

Posaconazole	The serum concentration of Belinostat can be increased when it is combined with Posaconazole.
Pralatrexate	The risk or severity of adverse effects can be increased when Belinostat is combined with Pralatrexate.
Pralsetinib	The serum concentration of Belinostat can be increased when it is combined with Pralsetinib.
Pramocaine	The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Pramocaine.
Prasugrel	The risk or severity of bleeding can be increased when Prasugrel is combined with Belinostat.
Pravastatin	The serum concentration of Belinostat can be increased when it is combined with Pravastatin.
Praziquantel	The metabolism of Praziquantel can be increased when combined with Belinostat.
Prednisolone	The risk or severity of adverse effects can be increased when Prednisolone is combined with Belinostat.
Prednisolone phosphate	The serum concentration of Prednisolone phosphate can be increased when it is combined with Belinostat.
Prednisone	The risk or severity of adverse effects can be increased when Prednisone is combined with Belinostat.
Prilocaine	The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Prilocaine.
Primaquine	The metabolism of Primaquine can be increased when combined with Belinostat.
Primidone	The metabolism of Belinostat can be increased when combined with Primidone.
Probenecid	The metabolism of Belinostat can be decreased when combined with Probenecid.
Procaine	The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Procaine.
Procarbazine	The risk or severity of adverse effects can be increased when Procarbazine is combined with Belinostat.
Promazine	The metabolism of Promazine can be increased when combined with Belinostat.
Propafenone	The serum concentration of Belinostat can be increased when it is combined with Propafenone.
Proparacaine	The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Proparacaine.
Propofol	The metabolism of Belinostat can be decreased when combined with Propofol.
Propoxycaine	The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Propoxycaine.
Propranolol	The metabolism of Propranolol can be increased when combined with Belinostat.
Propylthiouracil	The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Belinostat.
Protein C	The risk or severity of bleeding can be increased when Protein C is combined with Belinostat.
Protein S human	The risk or severity of bleeding can be increased when Protein S human is combined with Belinostat.
Quinidine	The serum concentration of Belinostat can be increased when it is combined with Quinidine.
Quinine	The serum concentration of Belinostat can be increased when it is combined with Quinine.
Rabies immune globulin,	The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Belinostat.
Rabies virus inactivated	The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Belinostat.
Rabies virus inactivated	The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Belinostat.
Raltitrexed	The risk or severity of adverse effects can be increased when Raltitrexed is combined with Belinostat.
Ramelteon	The metabolism of Ramelteon can be increased when combined with Belinostat.
Ranitidine	The metabolism of Ranitidine can be increased when combined with Belinostat.
Ranolazine	The serum concentration of Belinostat can be increased when it is combined with Ranolazine.
Rasagiline	The metabolism of Rasagiline can be increased when combined with Belinostat.
Ravulizumab	The risk or severity of adverse effects can be increased when Belinostat is combined with Ravulizumab.
Regorafenib	The metabolism of Belinostat can be decreased when combined with Regorafenib.
Relugolix	The serum concentration of Relugolix can be increased when it is combined with Belinostat.
Reserpine	The serum concentration of Belinostat can be increased when it is combined with Reserpine.
Reteplase	The risk or severity of bleeding can be increased when Reteplase is combined with Belinostat.
Revefenacin	The serum concentration of Revefenacin can be increased when it is combined with Belinostat.
Reviparin	The risk or severity of bleeding can be increased when Reviparin is combined with Belinostat.
Rifampicin	The metabolism of Belinostat can be increased when combined with Rifampicin.
Rifamycin	The serum concentration of Belinostat can be increased when it is combined with Rifamycin.
Rilonacept	The risk or severity of adverse effects can be increased when Belinostat is combined with Rilonacept.
Riluzole	The metabolism of Riluzole can be increased when combined with Belinostat.
Rimegepant	The serum concentration of Rimegepant can be increased when it is combined with Belinostat.
Riociguat	The serum concentration of Riociguat can be increased when it is combined with Belinostat.
Ripretinib	The serum concentration of Belinostat can be increased when it is combined with Ripretinib.
Risankizumab	The risk or severity of adverse effects can be increased when Belinostat is combined with Risankizumab.
Ritonavir	The metabolism of Belinostat can be increased when combined with Ritonavir.
Rituximab	The risk or severity of adverse effects can be increased when Rituximab is combined with Belinostat.
Rivaroxaban	The serum concentration of Rivaroxaban can be increased when it is combined with Belinostat.
Rofecoxib	The metabolism of Rofecoxib can be increased when combined with Belinostat.
Roflumilast	Roflumilast may increase the immunosuppressive activities of Belinostat.
Rolapitant	The serum concentration of Belinostat can be increased when it is combined with Rolapitant.
Romidepsin	The serum concentration of Romidepsin can be increased when it is combined with Belinostat.
Ropeginterferon alfa-2b	The risk or severity of adverse effects can be increased when Belinostat is combined with Ropeginterferon alfa-2b.
Ropinirole	The metabolism of Ropinirole can be increased when combined with Belinostat.
Ropivacaine	The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Ropivacaine.
Rotavirus vaccine	The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Belinostat.
Rubella virus vaccine	The risk or severity of infection can be increased when Rubella virus vaccine is combined with Belinostat.
Rucaparib	The metabolism of Rucaparib can be increased when combined with Belinostat.
Ruxolitinib	The risk or severity of adverse effects can be increased when Belinostat is combined with Ruxolitinib.
Sapropterin	The serum concentration of Belinostat can be increased when it is combined with Sapropterin.
Saquinavir	The serum concentration of Belinostat can be increased when it is combined with Saquinavir.
Sarecycline	The serum concentration of Belinostat can be increased when it is combined with Sarecycline.
Sarilumab	The risk or severity of adverse effects can be increased when Belinostat is combined with Sarilumab.
Satralizumab	The risk or severity of adverse effects can be increased when Belinostat is combined with Satralizumab.
Secukinumab	The risk or severity of adverse effects can be increased when Belinostat is combined with Secukinumab.
Selegiline	The metabolism of Selegiline can be increased when combined with Belinostat.
Selexipag	The serum concentration of Selexipag can be increased when it is combined with Belinostat.
Selumetinib	The serum concentration of Selumetinib can be increased when it is combined with Belinostat.
Sildenafil	The serum concentration of Belinostat can be increased when it is combined with Sildenafil.
Silodosin	The serum concentration of Silodosin can be increased when it is combined with Belinostat.
Siltuximab	The risk or severity of adverse effects can be increased when Belinostat is combined with Siltuximab.
Simeprevir	The serum concentration of Belinostat can be increased when it is combined with Simeprevir.
Simvastatin	The serum concentration of Belinostat can be increased when it is combined with Simvastatin.
Siponimod	The risk or severity of adverse effects can be increased when Belinostat is combined with Siponimod.
Sipuleucel-T	The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Belinostat.
Sirolimus	The risk or severity of adverse effects can be increased when Sirolimus is combined with Belinostat.
Sitagliptin	The serum concentration of Belinostat can be increased when it is combined with Sitagliptin.
Smallpox	The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Belinostat.
Sodium aurothiomalate	The metabolism of Belinostat can be decreased when combined with Sodium aurothiomalate.
Sodium citrate	The risk or severity of bleeding can be increased when Sodium citrate is combined with Belinostat.
Sofosbuvir	The serum concentration of Sofosbuvir can be increased when it is combined with Belinostat.
Sorafenib	The metabolism of Belinostat can be decreased when combined with Sorafenib.
Sotagliflozin	The serum concentration of Belinostat can be increased when it is combined with Sotagliflozin.
Sotorasib	The serum concentration of Belinostat can be increased when it is combined with Sotorasib.
Spesolimab	The risk or severity of adverse effects can be increased when Belinostat is combined with Spesolimab.
Stiripentol	The excretion of Belinostat can be decreased when combined with Stiripentol.
Streptokinase	The risk or severity of bleeding can be increased when Streptokinase is combined with Belinostat.
Streptozocin	The risk or severity of adverse effects can be increased when Streptozocin is combined with Belinostat.
Sulfamethoxazole	The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Belinostat.
Sulfasalazine	The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Belinostat.
Sulfinpyrazone	The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Belinostat.
Sulodexide	The risk or severity of bleeding can be increased when Sulodexide is combined with Belinostat.
Sunitinib	The risk or severity of adverse effects can be increased when Sunitinib is combined with Belinostat.
Suvorexant	The serum concentration of Belinostat can be increased when it is combined with Suvorexant.

Tacrolimus	Tacrolimus may increase the immunosuppressive activities of Belinostat.
Talazoparib	The serum concentration of Talazoparib can be increased when it is combined with Belinostat.
Tamoxifen	The metabolism of Tamoxifen can be increased when combined with Belinostat.
Tasimelteon	The metabolism of Tasimelteon can be increased when combined with Belinostat.
Tazemetostat	The serum concentration of Tazemetostat can be increased when it is combined with Belinostat.
Technetium	The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Belinostat.
Tedizolid phosphate	The risk or severity of myelosuppression can be increased when Belinostat is combined with Tedizolid phosphate.
Tegafur	The metabolism of Tegafur can be increased when combined with Belinostat.
Tegaserod	The serum concentration of Belinostat can be increased when it is combined with Tegaserod.
Telaprevir	The serum concentration of Belinostat can be increased when it is combined with Telaprevir.
Temozolomide	The risk or severity of adverse effects can be increased when Temozolomide is combined with Belinostat.
Temsirolimus	The risk or severity of adverse effects can be increased when Belinostat is combined with Temsirolimus.
Tenecteplase	The risk or severity of bleeding can be increased when Tenecteplase is combined with Belinostat.
Teniposide	The risk or severity of adverse effects can be increased when Teniposide is combined with Belinostat.
Tenofovir disoproxil	The serum concentration of Belinostat can be increased when it is combined with Tenofovir disoproxil.
Tepotinib	The serum concentration of Belinostat can be increased when it is combined with Tepotinib.
Teprotumumab	The risk or severity of adverse effects can be increased when Belinostat is combined with Teprotumumab.
Terbinafine	The metabolism of Terbinafine can be increased when combined with Belinostat.
Teriflunomide	The risk or severity of adverse effects can be increased when Belinostat is combined with Teriflunomide.
Testosterone propionate	The metabolism of Belinostat can be increased when combined with Testosterone propionate.
Tetracaine	The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Tetracaine.
Tezacaftor	The serum concentration of Tezacaftor can be increased when it is combined with Belinostat.
Thalidomide	The risk or severity of adverse effects can be increased when Thalidomide is combined with Belinostat.
Theophylline	The metabolism of Theophylline can be increased when combined with Belinostat.
Thiabendazole	The metabolism of Thiabendazole can be increased when combined with Belinostat.
Thiotepa	The risk or severity of adverse effects can be increased when Thiotepa is combined with Belinostat.
Thiothixene	The metabolism of Thiothixene can be increased when combined with Belinostat.
Ticagrelor	The serum concentration of Belinostat can be increased when it is combined with Ticagrelor.
encephalitis vaccine	The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Belinostat.
Ticlopidine	The risk or severity of bleeding can be increased when Ticlopidine is combined with Belinostat.
Tinzaparin	The risk or severity of bleeding can be increased when Tinzaparin is combined with Belinostat.
Tioguanine	The risk or severity of adverse effects can be increased when Tioguanine is combined with Belinostat.
Tipranavir	The metabolism of Belinostat can be increased when combined with Tipranavir.
Tirofiban	The risk or severity of bleeding can be increased when Tirofiban is combined with Belinostat.
Tivozanib	The serum concentration of Tivozanib can be increased when it is combined with Belinostat.
Tixocortol	The risk or severity of adverse effects can be increased when Belinostat is combined with Tixocortol.
Tizanidine	The metabolism of Tizanidine can be increased when combined with Belinostat.
Tocainide	The metabolism of Tocainide can be increased when combined with Belinostat.
Tocilizumab	The risk or severity of adverse effects can be increased when Belinostat is combined with Tocilizumab.
Tofacitinib	Belinostat may increase the immunosuppressive activities of Tofacitinib.
Tolvaptan	The serum concentration of Tolvaptan can be increased when it is combined with Belinostat.
Topotecan	The risk or severity of adverse effects can be increased when Topotecan is combined with Belinostat.
Toremifene	The serum concentration of Belinostat can be increased when it is combined with Toremifene.
Tositumomab	The risk or severity of adverse effects can be increased when Tositumomab is combined with Belinostat.
Trabectedin	The risk or severity of adverse effects can be increased when Belinostat is combined with Trabectedin.
Trastuzumab	Trastuzumab may increase the neutropenic activities of Belinostat.
Trastuzumab emtansine	The risk or severity of adverse effects can be increased when Belinostat is combined with Trastuzumab emtansine.
Tretinoin	The risk or severity of adverse effects can be increased when Tretinoin is combined with Belinostat.
Triamcinolone	The risk or severity of adverse effects can be increased when Triamcinolone is combined with Belinostat.
Triamterene	The metabolism of Triamterene can be increased when combined with Belinostat.
Trichlormethiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Belinostat.
Triclabendazole	The metabolism of Triclabendazole can be increased when combined with Belinostat.
Trifluoperazine	The metabolism of Trifluoperazine can be increased when combined with Belinostat.
Trifluridine	The risk or severity of adverse effects can be increased when Trifluridine is combined with Belinostat.
Triflusal	The risk or severity of bleeding can be increased when Triflusal is combined with Belinostat.
Trilaciclib	The serum concentration of Trilaciclib can be increased when it is combined with Belinostat.
Trilostane	The risk or severity of adverse effects can be increased when Trilostane is combined with Belinostat.
Trimipramine	The serum concentration of Trimipramine can be increased when it is combined with Belinostat.
Tucatinib	Tucatinib may decrease the excretion rate of Belinostat which could result in a higher serum level.
Typhoid vaccine	The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Belinostat.
Typhoid Vaccine Live	The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Belinostat.
Typhoid Vi polysaccharide	The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Belinostat.
Ubrogepant	The serum concentration of Ubrogepant can be increased when it is combined with Belinostat.
Umbralisib	The serum concentration of Belinostat can be increased when it is combined with Umbralisib.
Umeclidinium	The serum concentration of Umeclidinium can be increased when it is combined with Belinostat.
Upadacitinib	The risk or severity of adverse effects can be increased when Belinostat is combined with Upadacitinib.
Urokinase	The risk or severity of bleeding can be increased when Urokinase is combined with Belinostat.
Valproic acid	The metabolism of Belinostat can be decreased when combined with Valproic acid.
Vandetanib	The serum concentration of Belinostat can be increased when it is combined with Vandetanib.
Vardenafil	The serum concentration of Belinostat can be increased when it is combined with Vardenafil.
Varicella zoster vaccine	The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Belinostat.
Varicella zoster vaccine	The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Belinostat.
Vedolizumab	The risk or severity of adverse effects can be increased when Belinostat is combined with Vedolizumab.
Velpatasvir	The serum concentration of Belinostat can be increased when it is combined with Velpatasvir.
Vemurafenib	The serum concentration of Belinostat can be increased when it is combined with Vemurafenib.
Venetoclax	The serum concentration of Belinostat can be increased when it is combined with Venetoclax.
Verapamil	The serum concentration of Belinostat can be increased when it is combined with Verapamil.
Vibrio cholerae CVD	The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Belinostat.
Vilanterol	The risk or severity of adverse effects can be increased when Belinostat is combined with Vilanterol.
Vinblastine	The risk or severity of adverse effects can be increased when Vinblastine is combined with Belinostat.
Vincristine	The risk or severity of adverse effects can be increased when Vincristine is combined with Belinostat.
Vindesine	The risk or severity of adverse effects can be increased when Vindesine is combined with Belinostat.
Vinflunine	The serum concentration of Vinflunine can be increased when it is combined with Belinostat.
Vinorelbine	The risk or severity of adverse effects can be increased when Vinorelbine is combined with Belinostat.
Voclosporin	The risk or severity of adverse effects can be increased when Belinostat is combined with Voclosporin.
Vorapaxar	The serum concentration of Belinostat can be increased when it is combined with Vorapaxar.
Vorinostat	The risk or severity of gastrointestinal bleeding and thrombocytopenia can be increased when Belinostat is combined with Vorinostat.
Voxilaprevir	The serum concentration of Belinostat can be increased when it is combined with Voxilaprevir.
Warfarin	The metabolism of Warfarin can be increased when combined with Belinostat.

Pregnancy and Lactation

Pregnancy

Belinostat can cause fetal harm including teratogenicity and/or embryo-fetal death if administered during pregnancy, based on its mechanism of action. Reproductive animal studies have not been conducted with belinostat and there is no data in pregnant humans; however, it is a genotoxic drug that actively targets dividing cells. Women of childbearing potential should avoid becoming pregnant during treatment with belinostat. Advise pregnant women of the potential hazard to the fetus.

Breast-feeding

No information is available regarding the presence of belinostat in human milk, the effects on the breastfed child, or the effects on milk production. Due to the potential for serious adverse reactions in the nursing child, breastfeeding is not recommended during therapy or for 2 weeks after the last belinostat dose.

How should this medicine be used?

Belinostat comes as a powder to be mixed with liquid to be injected intravenously (into a vein) by a doctor or nurse in a hospital or clinic. It is usually given over a period of 30 minutes once daily on days 1 to 5 of a 21-day cycle. The length of your treatment depends on how well your body responds to the medication and the side effects that you experience.

Your doctor may need to adjust your dose or stop your treatment if you experience certain side effects. Be sure to tell your doctor how you are feeling during your treatment with the belinostat injection.

What special precautions should I follow?

Before receiving a belinostat injection,

• tell your doctor and pharmacist if you are allergic to belinostat injection, any other medications, or any of the ingredients in belinostat injection. Ask your pharmacist for a list of the ingredients.
• tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take or use while receiving belinostat injections. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
• tell your doctor if you have previously received treatment with other chemotherapy medications, if you have or think you may have any type of infection now, or if you have nausea, vomiting, or diarrhea. Also, tell your doctor if you have or have ever had kidney or liver disease.
• tell your doctor if you are pregnant, plan to become pregnant, or if you plan on fathering a child. You should not become pregnant while you are receiving belinostat injection. If you are female, you will need to take a pregnancy test before you start treatment and use birth control to prevent pregnancy during your treatment and for 6 months after your final dose. If you are a male, you and your partner should use birth control during your treatment with belinostat and for 3 months after your final dose. Talk to your doctor about birth control methods that you can use during your treatment. If you or your partner become pregnant while receiving a belinostat injection, call your doctor immediately. Belinostat injection may harm the fetus.
• tell your doctor if you are breastfeeding. You should not breastfeed while you are receiving a belinostat injection and for 2 weeks after the final dose.
• you should know that this medication may decrease fertility in men. Talk to your doctor about the risks of receiving a belinostat injection.
• if you are having surgery, including dental surgery, tell the doctor or dentist that you are receiving a belinostat injection.

When to Contact Your Doctor or Health Care Provider:

• Nausea (interferes with the ability to eat and is unrelieved with prescribed medication)
• Vomiting (vomiting more than 4-5 times in a 24-hour period)
• Constipation is unrelieved by laxative use.
• Diarrhea (4-6 episodes in a 24-hour period)
• Swelling of the feet or ankles. Sudden weight gain.
• Unable to urinate for more than 8 hours
• Unusual bleeding or bruising
• Black or tarry stools, or blood in your stools
• Blood in the urine
• Pain or burning with urination
• Extreme fatigue (unable to carry on self-care activities)
• Unable to eat or drink for 24 hours or have signs of dehydration: tiredness, thirst, dry mouth, dark and decreased amount of urine, or dizziness.

Always inform your healthcare provider if you experience any unusual symptoms.

• Before starting belinostat treatment, make sure you tell your doctor about any other medications you are taking (including prescription, over-the-counter, vitamins, herbal remedies, etc.). Do not take aspirin, or products containing aspirin unless your doctor specifically permits this.
• Please inform your doctor and dentist before local anesthetic or vasoconstrictor medications are used (for example, epinephrine, mepivacaine, and levonordefrin).
• Do not receive any kind of immunization or vaccination without your doctor’s approval while taking a belinostat.
• Inform your doctor if you are aware of having a homozygous UGT1A1*28 allele (a gene variance/mutation) as it may require a dose adjustment of the belinostat.
• Inform your healthcare professional if you are pregnant or may be pregnant prior to starting this treatment. Pregnancy category D (Belinostat may be hazardous to the fetus. Women who are pregnant or become pregnant must be advised of the potential hazard to the fetus.)
• For both men and women: Use contraceptives, and do not conceive a child (get pregnant) while taking belinostat. Barrier methods of contraception, such as condoms, are recommended.
• Do not breastfeed while taking a belinostat.

Self-Care Tips

• Drink at least two to three quarts of fluid every 24 hours, unless you are instructed otherwise.
• You may be at risk of infection so try to avoid crowds or people with colds, and report fever or any other signs of infection immediately to your healthcare provider.
• Wash your hands often.
• Use an electric razor and a soft toothbrush to minimize bleeding.
• Avoid contact sports or activities that could cause injury.
• To reduce nausea, take anti-nausea medications as prescribed by your doctor, and eat small, frequent meals.
• Avoid sun exposure. Wear SPF 15 (or higher) sunblock and protective clothing.
• In general, drinking alcoholic beverages should be kept to a minimum or avoided completely. You should discuss this with your doctor.
• Get plenty of rest.
• Maintain good nutrition.
• Remain active as you are able. Gentle exercise is encouraged such as a daily walk.
• If you experience symptoms or side effects, be sure to discuss them with your health care team. They can prescribe medications and/or offer other suggestions that are effective in managing such problems.

References

Show More